Fuller & Thaler Asset Management, Inc. Biomarin Pharmaceutical Inc Transaction History
Fuller & Thaler Asset Management, Inc.
- $25.4 Billion
- Q1 2025
A detailed history of Fuller & Thaler Asset Management, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Fuller & Thaler Asset Management, Inc. holds 836,397 shares of BMRN stock, worth $48.6 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
836,397Holding current value
$48.6 Million% of portfolio
0.23%Shares
1 transactions
Others Institutions Holding BMRN
# of Institutions
669Shares Held
184MCall Options Held
1.24MPut Options Held
957K-
Black Rock Inc. New York, NY22.7MShares$1.32 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19MShares$1.1 Billion0.03% of portfolio
-
Primecap Management CO Pasadena, CA17.8MShares$1.03 Billion1.06% of portfolio
-
Dodge & Cox San Francisco, CA15MShares$869 Million0.65% of portfolio
-
Viking Global Investors LP10.8MShares$627 Million2.55% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $10.8B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...